Home › Trial NCT04604691
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
- Trial IDNCT04604691
- StatusUnknown
- PhasePhase 1
- Study typeInterventional
- SponsorSeoul National University Hospital
- Enrollment20
- Start date2022-02-18
- ConditionsPediatric ALL, B Cell · Minimal Residual Disease
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.